A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults

Clinical Therapeutics

Volumn 28, Issue 4, 2006, Pages 517-526

  Wendt, Jeanette ^a   Cady, Roger ^b   Singer, Richard ^c   Peters, Kenneth ^d   Webster, Christopher ^e   Kori, Shashidhar ^e   Byrd, Susan ^e  

^a Northwest Neurospecialists   (United States)

^b HEADACHE CARE CENTER   (United States)

^c Neurology Clinical Research   (United States)

^d Northern California Headache Clinic   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

efficacy; migraine; pain; severity; sumatriptan; tolerability

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; GAMMA GLUTAMYLTRANSFERASE; PLACEBO; SUMATRIPTAN;

ABNORMAL SENSATION; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANALGESIA; ANXIETY; ARTICLE; BURNING SENSATION; CHEST TIGHTNESS; CHILL; CLINICAL TRIAL; COLD SENSATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEARING DISORDER; HEAT SENSATION; HEMOGLOBIN DETERMINATION; HOT FLUSH; HUMAN; HYPERHIDROSIS; INJECTION SITE REACTION; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALAISE; MALE; MIGRAINE; NAUSEA; NECK PAIN; NEUTROPHIL COUNT; NOSE DISEASE; PAIN; PARANASAL SINUS DISEASE; PHOTOPHOBIA; PRESSURE SENSATION; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; SKIN TINGLING; STATISTICAL SIGNIFICANCE; THROAT DISEASE; TONGUE DISEASE; VERTIGO; VOMITING; WEAKNESS;

ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; SEROTONIN AGENTS; SUMATRIPTAN;

EID: 33646887778     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.03.013     Document Type: Article

References (28)

1. Lipton R.B., and Bigal M.E. Migraine: Epidemiology, impact, and risk factors for progression. Headache 45 Suppl 1 (2005) S3-S13
2. Nissan G.R., and Diamond M.L. Advances in migraine treatment. J Am Osteopath Assoc 105 Suppl 2 (2005) 9S-15S
3. Lipton R.B., Hamelsky S.W., and Stewart W.F. Epidemiology and impact of migraine. In: Silberstein S.D., Lipton R.B., and Dalessio D.J. (Eds). Wolfs Headache and Other Head Pain. 7th ed. (2001), Oxford University Press, New York, NY 85-107
4. Lipton R.B., Stewart W.F., and Simon D. Medical consultation for migraine: Results from the American Migraine Study. Headache 38 (1998) 87-96
5. Stang P.E., and Von Korff M. The diagnoses of headache in primary care: Factors in the agreement of clinical and standardized diagnoses. Headache 34 (1994) 138-142
6. Imitrex injection [package insert] (2006). http://us.gsk.com/products/assets/us-imitrex
7. Relpax [package insert] (2006). http://www.relpax.com/pdf/ppi_final.pdf
8. Zomig nasal spray [package insert] (2006). http://www.astrazeneca-us.com/pi/zomignasalspray.pdf
9. Amerge tablets [package insert] (2006). http://us.gsk.com/products/assets/us_amerge.pdf
10. Maxalt [package insert] (2006). http://www.maxalt.com/maxalt/shared/documents/english/pi.pdf
11. Axert [package insert] (2006). http://www.axert.com/content/Documents/AxertPl.pdf#zoom=100
12. Frova [package insert] (2006). http://www.frova.com/pdfs/Frova_Insert_3000_02.pdf
13. Zomig tablets [package insert] (2006). http://www.astrazeneca_us.com/pi/Zomig.pdf
14. Ryan R., Elkind A., Baker C.C., et al. Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies. Neurology 49 (1997) 1225-1230
15. Peikert A., Becker W.J., Ashford E.A., et al. Sumatriptan nasal spray: A dose-ranging study in the acute treatment of migraine. Eur J Neurol 6 (1999) 43-49
16. Cady R.K., Wendt J.K., Kirchner J.R., et al. Treatment of acute migrainewith subcutaneous sumatriptan. JAMA 265 (1991) 2831-2835
17. Mushet G.R., Cady R.K., Baker C.C., et al. Efficacy and tolerability ofsubcutaneous sumatriptan administered using the IMITREX STATdose System. Clin Ther 18 (1996) 687-699
18. Spierings E.L., Rapoport A.M., Doddick D.W., and Charlesworth B. Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs 18 (2004) 1133-1141
19. Sheftell F., Ryan R., Pitman V., and Eletriptan Steering Committee. Efficacy, safety, and tolerability of oral eletriptan for the treatment of acute migraine: A multicen ter, double-blind, placebo-controlled study conducted in the United States. Headache 43 (2003) 202-213
20. Sheftell F.D., Dahlof C.G., Brandes J.L., et al. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. Clin Ther 27 (2005) 407-417
21. Ensink F.B., and Sumatriptan International Study Group. Subcutaneous sumatriptan in the acute treatment of migraine. J Neurol 238 Suppl 1 (1991) S66-S69
22. Visser W.H., Ferrari M.D., Bayliss E.M., et al., Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with subcutaneous suma triptan: First placebo controlled study. Cephalalgia 12 (1992) 308-313
23. Goadsby P.J., Lipton R.B., and Ferrari M.D. Migraine-current understanding and treatment. N Engl J Med 346 (2002) 257-270
24. Landy S.H., McGinnis J.E., and McDonald S.A. Pilot study evaluating preference for 3-mg versus 6-mg subcutaneous sumatriptan. Headache 45 (2005) 346-349
25. Mathew N.T., Dexter J., Couch J., et al., US Sumatriptan Research Group. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. Arch Neurol 49 (1992) 1271-1276
26. Thomson A.N., Arthur G.P., Bergin P.S., et al. Subcutaneous sumatriptan in acute treatment of migraine: A mul ticentre New Zealand trial. N Z Medj 106 (1993) 171-173
27. Headache Classification Committee of the International Headache Society. Classification and diagnos tic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8 Suppl 7 (1988) 1-96
28. Tfelt-Hansen P., Bousser M.G., Solomon S., et al. Guidelines for controlled trials of drugs in mi graine. International Headache Society Members' Handbook 2000 (1999), Scandinavian University Press, Oslo, Norway 118